Singlera Genomics struck a research and distribution agreement with EU‑based Pure Medical to commercialize its cell‑free DNA methylation assays, including the mTitan and mGuard platforms, across several European countries. Under the accord, Singlera and Pure Medical will pursue commercial deployment in hospitals and national healthcare systems and run collaborative research with local universities and clinical networks. Singlera says its methylation sequencing detects cancer‑associated cfDNA signals across multiple tumor types and expects the deal to accelerate early‑detection and monitoring access in western Europe. The agreement follows Singlera’s recent research collaboration with the University of Pittsburgh on pancreatic cancer detection.